4SC develops targeted small molecule drugs for the treatment of cancer in indications with a high unmet medical need. In doing so, we wish to offer affected patients treatment options that are more effective and better tolerated to provide a better quality of life.
The core 4SC product pipeline currently comprises two compounds in clinical development, resminostat and 4SC-202, and a third molecule, 4SC-208, that is in pre-clinical development.
CEO Jason Loveridge, Ph.D., on fast-to-market strategy for development of 4SC’s core assets resminostat, 4SC-202 and 4SC-208
as of May 2017
Resminostat is an orally administered histone deacetylase (HDAC) inhibitor with an innovative epigenetic mechanism of action that potentially represents a novel therapy for a broad spectrum of oncology indications, both in monotherapy and particularly in combination with other anti-cancer drugs.
4SC-202 is an orally administered small molecule for the treatment of cancer. The compound is an epigenetic modulator with a unique mechanism of action that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, which are believed to play significant roles in the regulation of aberrant cancer signaling pathways.
4SC-208 is a small molecule specifically targeting two kinases crucial for Hedgehog/GLI signaling. Inhibition of the Hedgehog/GLI pathway has emerged as a highly effective strategy in obstructing the tumorigenic capacity of cancer stem cells, responsible for metastasis and recurrence of tumors.
4SC is focused on developing targeted small molecule drugs with an epigenetic mode of action for the treatment of cancer. 4SC has out-licensed further products to national and international pharma and biotech companies.
Assets available for out-licensing
4SC is focused on developing targeted small molecule drugs with an epigenetic mode of action for the treatment of cancer. Further assets are available for partnering or out-licensing.